Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human breast cancer

Fredric J. Cohen, Andrea Manni, Patricia Glikman, Mary Bartholomew, Laurence Demers

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Recent evidence indicates that the antiestrogen tamoxifen (TAM) may inhibit breast cancer cell proliferation, at least in part, through suppression of the polyamine (PA) pathway. To directly test this hypothesis, we evaluated the effect of TAM administration on ornithine decarboxylase (ODC) activity, the rate-limiting enzyme in PA synthesis, as well as cellular PA levels in the hormone-responsive MCF-7 breast cancer cell line in culture. In detailed time course studies, we observed that TAM significantly inhibited the rise in ODC activity observed in control cells following a medium change. Chronic treatment with escalating amounts of TAM caused a dose-related decrease in tumor pools of putrescine and spermidine, while spermine levels were unaffected. The TAM effects on ODC activity and PA pools were reversible with exogenous estradiol administration. However, addition of putrescine to TAM-treated cells did not result in a reversal of the antiproliferative effect of TAM, despite repletion of cellular PA pools. Administration of TAM to the hormone-independent MDA-MB-231 breast cancer cell line did not suppress ODC activity or cellular PA levels despite induction, at high concentrations, of an estradiol-irreversible inhibition of proliferation. We conclude that, in the hormone-responsive MCF-7 breast cancer cell line, TAM causes a significant suppression of the PA pathway, the relation of which, if any, to its antiproliferative action remains obscure. This effect seems to be mediated through the estrogen receptor and does not appear to be a nonspecific consequence of inhibition of cell proliferation.

Original languageEnglish (US)
Pages (from-to)6819-6825
Number of pages7
JournalCancer Research
Volume48
Issue number23
StatePublished - Jan 1 1988

Fingerprint

Estrogen Receptor Modulators
Polyamines
Tamoxifen
Breast Neoplasms
Ornithine Decarboxylase
Growth
Putrescine
Hormones
Cell Line
Estradiol
Cell Proliferation
Spermidine
Spermine
Estrogen Receptors

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Cohen, F. J., Manni, A., Glikman, P., Bartholomew, M., & Demers, L. (1988). Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human breast cancer. Cancer Research, 48(23), 6819-6825.
Cohen, Fredric J. ; Manni, Andrea ; Glikman, Patricia ; Bartholomew, Mary ; Demers, Laurence. / Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human breast cancer. In: Cancer Research. 1988 ; Vol. 48, No. 23. pp. 6819-6825.
@article{2de0f0d99e7d4777859778a6a6f97671,
title = "Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human breast cancer",
abstract = "Recent evidence indicates that the antiestrogen tamoxifen (TAM) may inhibit breast cancer cell proliferation, at least in part, through suppression of the polyamine (PA) pathway. To directly test this hypothesis, we evaluated the effect of TAM administration on ornithine decarboxylase (ODC) activity, the rate-limiting enzyme in PA synthesis, as well as cellular PA levels in the hormone-responsive MCF-7 breast cancer cell line in culture. In detailed time course studies, we observed that TAM significantly inhibited the rise in ODC activity observed in control cells following a medium change. Chronic treatment with escalating amounts of TAM caused a dose-related decrease in tumor pools of putrescine and spermidine, while spermine levels were unaffected. The TAM effects on ODC activity and PA pools were reversible with exogenous estradiol administration. However, addition of putrescine to TAM-treated cells did not result in a reversal of the antiproliferative effect of TAM, despite repletion of cellular PA pools. Administration of TAM to the hormone-independent MDA-MB-231 breast cancer cell line did not suppress ODC activity or cellular PA levels despite induction, at high concentrations, of an estradiol-irreversible inhibition of proliferation. We conclude that, in the hormone-responsive MCF-7 breast cancer cell line, TAM causes a significant suppression of the PA pathway, the relation of which, if any, to its antiproliferative action remains obscure. This effect seems to be mediated through the estrogen receptor and does not appear to be a nonspecific consequence of inhibition of cell proliferation.",
author = "Cohen, {Fredric J.} and Andrea Manni and Patricia Glikman and Mary Bartholomew and Laurence Demers",
year = "1988",
month = "1",
day = "1",
language = "English (US)",
volume = "48",
pages = "6819--6825",
journal = "Cancer Research",
issn = "0008-5472",
number = "23",

}

Cohen, FJ, Manni, A, Glikman, P, Bartholomew, M & Demers, L 1988, 'Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human breast cancer', Cancer Research, vol. 48, no. 23, pp. 6819-6825.

Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human breast cancer. / Cohen, Fredric J.; Manni, Andrea; Glikman, Patricia; Bartholomew, Mary; Demers, Laurence.

In: Cancer Research, Vol. 48, No. 23, 01.01.1988, p. 6819-6825.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Involvement of the polyamine pathway in antiestrogen-induced growth inhibition of human breast cancer

AU - Cohen, Fredric J.

AU - Manni, Andrea

AU - Glikman, Patricia

AU - Bartholomew, Mary

AU - Demers, Laurence

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Recent evidence indicates that the antiestrogen tamoxifen (TAM) may inhibit breast cancer cell proliferation, at least in part, through suppression of the polyamine (PA) pathway. To directly test this hypothesis, we evaluated the effect of TAM administration on ornithine decarboxylase (ODC) activity, the rate-limiting enzyme in PA synthesis, as well as cellular PA levels in the hormone-responsive MCF-7 breast cancer cell line in culture. In detailed time course studies, we observed that TAM significantly inhibited the rise in ODC activity observed in control cells following a medium change. Chronic treatment with escalating amounts of TAM caused a dose-related decrease in tumor pools of putrescine and spermidine, while spermine levels were unaffected. The TAM effects on ODC activity and PA pools were reversible with exogenous estradiol administration. However, addition of putrescine to TAM-treated cells did not result in a reversal of the antiproliferative effect of TAM, despite repletion of cellular PA pools. Administration of TAM to the hormone-independent MDA-MB-231 breast cancer cell line did not suppress ODC activity or cellular PA levels despite induction, at high concentrations, of an estradiol-irreversible inhibition of proliferation. We conclude that, in the hormone-responsive MCF-7 breast cancer cell line, TAM causes a significant suppression of the PA pathway, the relation of which, if any, to its antiproliferative action remains obscure. This effect seems to be mediated through the estrogen receptor and does not appear to be a nonspecific consequence of inhibition of cell proliferation.

AB - Recent evidence indicates that the antiestrogen tamoxifen (TAM) may inhibit breast cancer cell proliferation, at least in part, through suppression of the polyamine (PA) pathway. To directly test this hypothesis, we evaluated the effect of TAM administration on ornithine decarboxylase (ODC) activity, the rate-limiting enzyme in PA synthesis, as well as cellular PA levels in the hormone-responsive MCF-7 breast cancer cell line in culture. In detailed time course studies, we observed that TAM significantly inhibited the rise in ODC activity observed in control cells following a medium change. Chronic treatment with escalating amounts of TAM caused a dose-related decrease in tumor pools of putrescine and spermidine, while spermine levels were unaffected. The TAM effects on ODC activity and PA pools were reversible with exogenous estradiol administration. However, addition of putrescine to TAM-treated cells did not result in a reversal of the antiproliferative effect of TAM, despite repletion of cellular PA pools. Administration of TAM to the hormone-independent MDA-MB-231 breast cancer cell line did not suppress ODC activity or cellular PA levels despite induction, at high concentrations, of an estradiol-irreversible inhibition of proliferation. We conclude that, in the hormone-responsive MCF-7 breast cancer cell line, TAM causes a significant suppression of the PA pathway, the relation of which, if any, to its antiproliferative action remains obscure. This effect seems to be mediated through the estrogen receptor and does not appear to be a nonspecific consequence of inhibition of cell proliferation.

UR - http://www.scopus.com/inward/record.url?scp=0024212339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024212339&partnerID=8YFLogxK

M3 - Article

C2 - 3180091

AN - SCOPUS:0024212339

VL - 48

SP - 6819

EP - 6825

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 23

ER -